Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Time to Secondary Resistance to Trabectedin After Interruption Versus Continuation in Responding Patients With Liposarcoma, Leiomyosarcoma and Synovial Sarcoma

NCT03773510 is registered in ClinicalTrials.gov with Italian Sarcoma Group as lead sponsor.

NCT NCT03773510
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03773510 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Time to Secondary Resistance to Trabectedin After Interruption Versus Continuation in Responding Patients With Liposarcoma, Leiomyosarcoma and Synovial Sarcoma
Lead sponsor
Italian Sarcoma Group
Phase
Phase 3
Overall status
Withdrawn
Start date
February 28, 2019
Completion date
October 1, 2025
Enrollment
0 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

leiomyosarcoma, liposarcoma, synovial sarcoma